---
title: "Brief News: BAIYUNSHAN PH spent 750 million to acquire a 10% stake in NPC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259245091.md"
description: "Guangzhou Baiyunshan Pharmaceutical Group, through its subsidiary Guangyao Phase II Fund, acquired an 11.04% stake in NPC for 749 million yuan. NPC is primarily engaged in pharmaceutical wholesale, retail, and logistics, covering multiple provinces and cities. Baiyunshan stated that this acquisition will optimize its layout in the East China region, enhance competitive advantages, and promote growth in its pharmaceutical manufacturing business. On Monday, Baiyunshan's stock price rose slightly by 0.4%, closing at HKD 18.05"
datetime: "2025-09-29T02:35:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259245091.md)
  - [en](https://longbridge.com/en/news/259245091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259245091.md)
---

# Brief News: BAIYUNSHAN PH spent 750 million to acquire a 10% stake in NPC

Pharmaceutical company **Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.** (0874.HK, 600332.SH) **announced on Sunday** that it has acquired an 11.04% stake in **Nanjing Pharmaceutical** (600713.SH) through its subsidiary, the Guangyao Phase II Fund, for a price of 749 million yuan.

Nanjing Pharmaceutical's main businesses include pharmaceutical wholesale, pharmaceutical retail, pharmaceutical "Internet Plus," and third-party logistics, with a network covering Jiangsu, Anhui, Hubei, Fujian, and Kunming. The company has been listed on the Shanghai Stock Exchange since 1996.

Baiyunshan pointed out that through cooperation in capital, distribution channel construction, and the field of traditional Chinese medicine, it aims to optimize its layout in the East China region, enhance the competitive advantage of its pharmaceutical business, and drive growth in its pharmaceutical manufacturing business for sustained development.

On Monday, Baiyunshan's stock rose slightly by 0.4% to HKD 18.05, with the company's stock price fluctuating between HKD 15 and HKD 19 this year.

_Liu Zhiheng_

### Related Stocks

- [600332.CN](https://longbridge.com/en/quote/600332.CN.md)
- [00874.HK](https://longbridge.com/en/quote/00874.HK.md)
- [600713.CN](https://longbridge.com/en/quote/600713.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Can the business model of operators launching AI token packages be viable?](https://longbridge.com/en/news/286700860.md)
- [09:09 ETPacific Mind Health Releases Free Guide to Help People Start Conversations About Mental Health](https://longbridge.com/en/news/287072254.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [Funnel earns 2026 NAA Top Employers recognition and ranks No. 11 on Tampa Bay Business Journal’s Best Places to Work list](https://longbridge.com/en/news/287064595.md)